Therefore, to test if this mechanism could be responsible of β-catenin and AKT degradation upon CK1α inhibition also in MM cells, we treated INA-6 cells with D4476 and the pan-caspase inhibitor Z-VAD-FMK. Here, CSNK1A1 is linked to Miyoshi myopathy.